DM
ACAD icon

Deerfield Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Deerfield Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,154
Closed -$541K – 110
2024
Q3 		$541K Buy
+35,154
New +$586K 0.01% 275
2024
Q1 		– Sell
-9,728
Closed -$305K – 368
2023
Q4 		$305K Buy
+9,728
New +$232K 0.01% 117
2015
Q2 		– Sell
-49,400
Closed -$1.61M – 124
2015
Q1 		$1.61M Buy
+49,400
New +$1.7M 0.05% 104
2013
Q3 		– Sell
-1,067,115
Closed -$19.4M – 114
2013
Q2 		$19.4M Buy
+1,067,115
New +$14.7M 0.91% 49

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Deerfield Management's ACAD Position: Q4 2024 in Review

Deerfield Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 35,154 shares — an estimated $541K sold.

Deerfield Management first reported a position in ACAD in Q2 2013 and held it in 4 quarters. The position peaked at $19.4M in Q2 2013. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • Deerfield Management reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 35,154 Acadia Pharmaceuticals shares in Q4 2024, an estimated $541K.
  • Deerfield Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Deerfield Management's Acadia Pharmaceuticals position peaked at $19.4M in Q2 2013.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.